Acumen Pharmaceuticals, Inc.
ABOS
$1.08
-$0.02-1.82%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -102.33M | -81.67M | -64.86M | -55.94M | -52.37M |
| Total Depreciation and Amortization | 178.00K | 173.00K | 168.00K | 176.00K | 184.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.28M | 4.70M | 4.20M | 5.24M | 5.26M |
| Change in Net Operating Assets | 11.65M | 9.49M | 4.87M | -225.00K | 3.87M |
| Cash from Operations | -86.22M | -67.31M | -55.62M | -50.75M | -43.06M |
| Capital Expenditure | -16.00K | -30.00K | -37.00K | -32.00K | -21.00K |
| Sale of Property, Plant, and Equipment | -- | 0.00 | 3.00K | 3.00K | 3.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 48.04M | -30.41M | -112.28M | -138.92M | -171.65M |
| Cash from Investing | 48.03M | -30.44M | -112.31M | -138.95M | -171.67M |
| Total Debt Issued | -- | 30.00M | 30.00M | 30.00M | 30.00M |
| Total Debt Repaid | -739.00K | -739.00K | -739.00K | -739.00K | -- |
| Issuance of Common Stock | 7.94M | 7.94M | 130.56M | 130.56M | 122.62M |
| Repurchase of Common Stock | -41.00K | -422.00K | -422.00K | -422.00K | -390.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -230.00K | -706.00K | -519.00K | -536.00K | -476.00K |
| Cash from Financing | 6.93M | 36.07M | 158.88M | 158.86M | 151.75M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -31.26M | -61.69M | -9.06M | -30.84M | -62.98M |